Attributes | Values |
---|
rdf:type
| |
Description
| - Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350 and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches have been evaluate
- Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350 and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches have been evaluate (en)
|
Title
| - Treatment of Chronic Hepatitis B in 2002
- Treatment of Chronic Hepatitis B in 2002 (en)
|
skos:prefLabel
| - Treatment of Chronic Hepatitis B in 2002
- Treatment of Chronic Hepatitis B in 2002 (en)
|
skos:notation
| - RIV/65269705:_____/03:00007828!RIV/2004/MZ0/L43004/N
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/65269705:_____/03:00007828
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - chronic hepatitis B;alpha-interferon;lamivudine;adefovir dipivoxil;nucleoside analogs;pegylated interferon (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Bratislavské lekárské listy
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...ocetUcastnikuAkce
| |
http://linked.open...nichUcastnikuAkce
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Husa, Petr
- Husová, Libuše
|
issn
| |
number of pages
| |